Building the Case for Biopharma Industry Investment in Strep A Vaccine Development

A global health consortium required support in attracting greater industry investment into the traditionally underfunded area of Strep A vaccine development.

As part of a collaboration involving the WHO, Wellcome Trust, International Vaccine Institute, Harvard School of Public Health and other members of the Strep A Global Vaccine Consortium (SAVAC), Shift Health developed an innovative vaccine demand forecast and return on investment model to bolster the business case for investment in Strep A vaccine R&D by biopharma companies and developing country vaccine manufacturers. To inform the model, we interviewed vaccine developers, public health officials, global health funders and vaccine decision-makers around the world to assess awareness of and need for a Strep A vaccine, as well as R&D and access considerations.

Shift Health’s tailored model and business case revealed strong commercial potential for Strep A vaccines and will be used to support engagement efforts aimed at increasing Strep A vaccine funding.